Viberzi denied for missing prior authorization by Cigna?

Cigna's specific coverage criteria for viberzi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Requires Prior Authorization for Viberzi

Cigna requires prior authorization (PA) for Viberzi (eluxadoline) as a condition of coverage — meaning the prescription cannot be dispensed at a plan-covered cost until Cigna reviews and approves a clinical justification in advance. A PA denial (or failure to respond in time) often occurs because the initial submission was incomplete, did not address all of Cigna's required clinical criteria, or was submitted without adequate supporting documentation.

Prior-auth denials are highly appealable because the clinical information required is almost always obtainable from your medical chart. Most PA denials for Viberzi come down to documentation gaps rather than a genuine clinical ineligibility.

## Your Federal Appeal Rights

Under ACA §2719, a PA denial is a coverage denial subject to internal appeal and independent external review. Under ERISA §503, self-funded employer plans must provide full-and-fair review. The external-review window is generally approximately four months from the denial notice. Expedited review is available — and particularly important here — if waiting for standard timelines would seriously jeopardize your health or ability to obtain treatment.

## The Appeal Process

1. Request the PA denial in writing. Obtain the exact criteria Cigna applied and identify which specific criterion was deemed unmet. 2. Resubmission vs. formal appeal. In some cases, a PA denial can be resolved by resubmitting with corrected documentation before filing a formal appeal. Ask Cigna's PA department whether a peer-to-peer review with your prescriber is available — this is often the fastest path. 3. Level 1 internal appeal. Submit the formal written appeal with a complete documentation package within the deadline on your denial notice. 4. External review. If the internal appeal fails, file for IRO review immediately.

## Documentation to Gather

• Diagnosis confirmation: Chart notes, relevant diagnostic workup confirming IBS-D.
• Clinical severity: Recent visit notes documenting symptom frequency, severity, and functional impact.
• Step-therapy history: For each prior IBS-D therapy Cigna requires, provide start date, end date, dose used, and documented reason for discontinuation or inadequate response.
• Prescriber medical-necessity letter: Should address each PA criterion by name and provide a chart-based answer for each.
• Peer-to-peer availability: Ask your prescriber whether they are willing to conduct a peer-to-peer call with Cigna's medical director — this often resolves PA denials at the pre-appeal stage.

## Criteria-Mapping Structure

Obtain Cigna's current prior-authorization criteria for Viberzi/eluxadoline — these are often published in Cigna's clinical coverage policies or can be requested from the PA department. Map each criterion to a specific chart fact. Verify exact clinical requirements against the FDA-approved prescribing label; the label's approved indication and any clinical use considerations are the primary reference point for what constitutes appropriate patient selection.